Compare CTSO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | CELU |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 26.5M |
| IPO Year | 2008 | 2019 |
| Metric | CTSO | CELU |
|---|---|---|
| Price | $4.52 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 182.4K |
| Earning Date | 11-12-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $22,503,908.00 | ★ $26,550,000.00 |
| Revenue This Year | $2.14 | $165.42 |
| Revenue Next Year | $16.24 | $305.36 |
| P/E Ratio | ★ N/A | $11.70 |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.30 | $0.46 |
| 52 Week High | $7.44 | $2.55 |
| Indicator | CTSO | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 25.58 |
| Support Level | $2.88 | N/A |
| Resistance Level | $7.20 | $0.83 |
| Average True Range (ATR) | 0.79 | 0.10 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 15.43 | 6.38 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.